Table 1 Patient baseline characteristics in the SAMBA trial
Patient characteristics, n, (%) | n = 24 |
|---|---|
Age (years), median (IQR) | 77 (71–90) |
AML | 19 (79%) |
MDS | 5 (21%) |
Cytogenetics, n, (%) | |
Normal karyotype | 12 (50%) |
Abnormal karyotype | 12 (50%) |
Complex karyotype (≥3) | 5 (21%) |
ELN 2017 AML risk classification (n = 19) | |
Favorable | 2 (10%) |
Intermediate | 8 (43%) |
Unfavorable | 9 (47%) |
Somatic mutations, n, (%) | |
No mutation | 2 (8%) |
≥1 mutation | 22 (92%) |
≥2 mutations | 16 (67%) |
≥3 mutations | 15 (63%) |
Epigenetic | |
ASXL1 | 7 (29%) |
TET2 | 6 (25%) |
EZH2 | 4 (17%) |
DNMT3A | 3 (13%) |
IDH1 | 3 (13%) |
BCORL1 | 2 (8%) |
IDH2 | 2 (8%) |
BCOR | 2 (8%) |
Cohesin | |
STAG2 | 4 (17%) |
RAD21 | 1 (4%) |
Splicing | |
SRSF2 | 4 (17%) |
SF3B1 | 2 (8%) |
U2AF1 | 2 (8%) |
ZRSR2 | 2 (8%) |
Transcription factors | |
RUNX1 | 3 (13%) |
CEPBA | 3 (13%) |
CUX1 | 1 (4%) |
GATA2 | 1 (4%) |
TP53 | |
TP53 | 7 (29%) |
Signaling | |
NRAS | 2 (8%) |
KRAS | 2 (8%) |
PTPN11 | 2 (8%) |
JAK2 | 1 (4%) |
Others | |
NPM1 | 2 (8%) |
PHF6 | 2 (8%) |
KDM6A | 1 (4%) |
NOTCH1 | 1 (4%) |
Blood counts, median, (range) | |
WBC (/nl) | 2.51 (0.37–12.64) |
Hemoglobin (g/dl) | 9.25 (8.05–11.7) |
PLT (/nl) | 28 (4–1018) |
ANC (/nl) | 0.59 (0.0–5.59) |
Lymphocytes (/nl) | 0.80 (0.024–4) |
BM blasts (%) | 27 (7–89) |
Interval from diagnosis (years) | 1.76 (0.61–7.82) |
Therapy outcome, median, (range) | |
Days on treatment | 57 (1–374) |
Cycles completed | 3 (1–26) |
